肾盂输尿管癌蛋白激酶C表达的临床意义  

Clinical significance of protein kinase C expression in renal pelvic and ureteral carcinoma

作　　者：孔垂泽[1] 李泽良[1] 刘同才[1] 何三光[1] 杨涛[1] 

机构地区：[1]中国医科大学第一临床学院泌尿外科,沈阳110001

出　　处：《中华泌尿外科杂志》2000年第10期609-611,共3页Chinese Journal of Urology

摘　　要：目的　探讨蛋白激酶C(PKC)、PKCα在肾盂输尿管癌中表达的临床意义。　方法　采用免疫组化SABC法和原位杂交技术检测 45例肾盂输尿管癌中PKC、PKCα表达。　结果　肾盂输尿管癌PKC、PKCα阳性表达率分别为 6 0 .0 %和 5 7.8%。其中T2 ～T3 为 6 8.6 % (2 4/ 35 )、6 8 6 %(2 4/ 35 ) ,T1为 30 .0 % (3/ 10 )、2 0 0 % (2 / 10 ) ,P <0 .0 5。G2 ～G3 患者为 6 6 .7% (2 6 / 39)、6 1 4% (2 5 /39) ,G1为 16 .7% (1/ 6 )、16 7(1/ 6 ) ,P <0 .0 5。术后再发膀胱癌者PKC、PKCα阳性表达率为 83 3 %(15 / 18)、77 8% (14/ 18) ,术后未再发者PKC、PKCα阳性表达率为 44 4% (12 / 2 7)、44 .4% (12 / 2 7) ,P<0 0 5。PKC、PKCα阳性表达者生存率明显低于阴性表达者 ,P <0 0 5。　结论　PKC、PKCα阳性表达与肾盂输尿管癌病理分期、细胞分级、术后再发膀胱癌及预后有关 。Objective To study the clinical significance of protein kinase C expression in renal pelvic and ureteral carcinoma. Methods Protein kinase C (PKC) was detected by immunohistochemical method and PKC alpha by in situ hybridization. Results Positive rate of PKC and PKC alpha was 60.0% and 57.8% respectively in renal pelvic and ureteral carcinoma.Positive rate of PKC is 68.8%(24/35) in stage T 2～T 3 tumors and 30% (3/10) in T 1 ( P <0.05),being 66.7%(26/39) in G 2～G 3 tumors and 16.7%(1/6) in G 1 ( P <0.05).Positive rate of PKC alpha in T 2～T 3 tumors was 68.6% (24/35) and 20.0%(2/10) in T 1 ( P <0.05),being 64.1%(25/39) in G 2～G 3 and 16.7%(1/6) in G 1 ( P <0.05).Post operative occurence of bladder cancer in PKC positive group was 55.6%(15/27),higher than that in PKC negative group,which was 16.7%(3/18) ( P <0.05).Post operative occurence of bladder cancer in the PKC alpha positive group was 53.9%(14/26),also higher than that in the PKC negative group (21.1%, P <0.05). Conclusions Expressions of PKC and PKC alpha are related to the pathological grade,clinical stage and postoperative occurrence of bladder carcinoma in renal pelvic and ureteral carcinoma.

关 键 词：肾盂输尿管癌 蛋白激酶C 预后 

分 类 号：R737.11[医药卫生—肿瘤]